Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
grade F 4.2 -5.41% -0.24
ZIOP closed down 5.41 percent on Monday, November 11, 2019, on 62 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ZIOP trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish -5.41%
Crossed Above 200 DMA Bullish -5.41%
Crossed Above 50 DMA Bullish -5.41%
Expansion Pivot Buy Setup Bullish Swing Setup -5.41%

Older signals for ZIOP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.
Medicine Biopharmaceutical Cancer Melanoma Cancer Therapies Metastatic Melanoma Metastatic Breast Cancer Metastatic Small Cell Lung Cancer Neoplasms
Is ZIOP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.25
52 Week Low 1.56
Average Volume 1,402,859
200-Day Moving Average 4.4193
50-Day Moving Average 4.3383
20-Day Moving Average 4.2205
10-Day Moving Average 4.2725
Average True Range 0.2568
ADX 12.58
+DI 13.2571
-DI 17.7197
Chandelier Exit (Long, 3 ATRs ) 3.7607
Chandelier Exit (Short, 3 ATRs ) 4.4904
Upper Bollinger Band 4.4965
Lower Bollinger Band 3.9445
Percent B (%b) 0.46
BandWidth 13.079019
MACD Line -0.0137
MACD Signal Line -0.0374
MACD Histogram 0.0237
Fundamentals Value
Market Cap 590.65 Million
Num Shares 141 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -8.40
Price-to-Sales 98.61
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.55
Resistance 3 (R3) 4.58 4.49 4.49
Resistance 2 (R2) 4.49 4.41 4.48 4.47
Resistance 1 (R1) 4.35 4.35 4.31 4.32 4.45
Pivot Point 4.26 4.26 4.24 4.25 4.26
Support 1 (S1) 4.12 4.18 4.08 4.09 3.95
Support 2 (S2) 4.03 4.12 4.02 3.93
Support 3 (S3) 3.89 4.03 3.91
Support 4 (S4) 3.86